Ivana Knyght is a seasoned professional in the Life Sciences industry. As the Vice President and Global Life Sciences Incubator Lead at Capgemini, she is at the forefront of driving innovation and transformation in the Biopharma sector. Ivana is a strategic thinker with a proven track record of successfully establishing and leading hyperscaler alliances and delivering cutting-edge solutions to address the industry's most pressing challenges.
With a deep understanding of data, AI, and biotechnology, Ivana is passionate about leveraging technology to revolutionize R&D. Her expertise lies in developing and implementing digital strategies that optimize data flow, processes, operations, improve patient outcomes, and drive business growth. Ivana is a thought leader in the field, regularly sharing her insights at industry conferences and events.
At BioTechX Europe 2025 Ivana will be sharing her expertise on how organizations can harness the power of data and AI to drive innovation and enhance speed and precision in drug discovery and development. Her session promises to provide valuable insights and practical strategies for industry professionals looking to stay ahead in this rapidly evolving landscape.
By background Ivana is a researcher, healthcare professional and data expert working across R&D. She completed her PhD and postdoctoral studies in Molecular Biophysics focussing on drug discovery. She has led a number of clinical development business and data transformations where the objective was to accelerate the cycle time. She is the Capagemini Invent Life Sciences relationship lead for NVIDIA.
With the FDA accelerating its AI initiatives, the industry stands at a pivotal moment to revolutionize the speed and efficiency of bringing new therapies to market. Join the panel discussion lead by Ivana Knyght, Ph.D., from Capgemini Invent and discover how generative AI is reshaping de novo molecule design, target identification and validation, toxicity prediction, in silico simulations, and high-content screening.